VEGFA and diabetic retinopathy: A most recent meta-analysis from JAMA Ophthalmology revealed that administration of anti-VEGF agents increased the risk of non-ocular hemorrhage in AMD patients (OR = 1.46, 95% CI 1.01–2.10); as well as increased risk of death in patients with diabetic retinopathy (OR = 1.80, 95% CI 1.03–3.16)39.